ILMN:NGS-Illumina Inc.

EQUITY | Medical Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 310.7

Change

+4.92 (+1.61)%

Market Cap

USD 19.79B

Volume

0.84M

Analyst Target

USD 336.47
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Illumina Inc provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-19 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing ILMN

CURE:XETRA VanEck Genomics and Healt.. 6.18 % 0.00 %

-0.08 (-0.47%)

USD 6.89M
DDOC:XETRA Global X Telemedicine & D.. 4.28 % 0.00 %

-0.03 (-0.47%)

USD 5.32M
DDOC:F Global X Telemedicine & D.. 4.28 % 0.00 %

-0.05 (-0.47%)

USD 5.32M
EDOC:SW Global X Telemedicine & D.. 4.28 % 0.00 %

-0.02 (-0.47%)

USD 4.92M
EDOC:LSE Global X Telemedicine & D.. 4.19 % 0.00 %

N/A

USD 5.32M
EDOG:LSE Global X Telemedicine & D.. 4.19 % 0.00 %

-0.01 (-0.47%)

USD 5.32M
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.02 % 0.00 %

-0.20 (-0.47%)

USD 3.51M
GNOG:LSE Global X Genomics & Biote.. 3.69 % 0.00 %

-0.09 (-0.47%)

USD 8.88M
GN0M:XETRA Global X Genomics & Biote.. 3.60 % 0.00 %

-0.12 (-0.47%)

USD 8.88M
GNOM:SW Global X Genomics & Biote.. 3.60 % 0.00 %

-0.11 (-0.47%)

USD 6.73M
CDNA:CA CI Bio-Revolution ETF 3.35 % 0.00 %

N/A

CAD 5.34M
2B70:F iShares NASDAQ US Biotech.. 2.22 % 0.00 %

-0.05 (-0.47%)

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 2.22 % 0.00 %

-0.06 (-0.47%)

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 2.15 % 0.00 %

-0.07 (-0.47%)

USD 0.46B
XMLH:F Legal & General Ucits Etf.. 1.98 % 0.00 %

-0.05 (-0.47%)

USD 0.08B
DOCT:SW L&G Healthcare Breakthrou.. 1.98 % 0.00 %

-0.10 (-0.47%)

USD 0.08B
ROBO:SW L&G ROBO Global Robotics .. 1.79 % 0.00 %

-0.09 (-0.47%)

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 1.19B
ALFA 0.00 % 0.65 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

-0.91 (-0.47%)

USD 0.45B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.60 (-0.47%)

USD 0.10B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.25 (+-0.47%)

USD 3.90M
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-1.08 (-0.47%)

USD 7.79B
IBCE 0.00 % 0.10 %

N/A

N/A
IBDD 0.00 % 0.10 %

N/A

N/A
QQEW First Trust NASDAQ-100 Eq.. 0.00 % 0.60 %

-1.17 (-0.47%)

USD 2.19B
QQXT First Trust NASDAQ-100 Ex.. 0.00 % 0.60 %

-0.29 (-0.47%)

USD 0.15B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.05 (-0.47%)

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.05 (-0.47%)

USD 0.49B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.06 (-0.47%)

USD 0.49B
ZBIO 0.00 % 0.95 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

-0.01 (-0.47%)

USD 0.05B
BBIG:CA 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.10 (-0.47%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.59% 28% F 29% F
Dividend Return N/A N/A N/A N/A F
Total Return 3.59% 28% F 28% F
Trailing 12 Months  
Capital Gain 24.91% 65% D 86% B+
Dividend Return N/A N/A N/A N/A F
Total Return 24.91% 65% D 85% B
Trailing 5 Years  
Capital Gain 92.26% 69% C- 80% B-
Dividend Return N/A N/A N/A N/A F
Total Return 92.26% 69% C- 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 19.04% 69% C- 77% C+
Dividend Return 19.04% 69% C- 75% C
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 31.50% 60% D- 40% F
Risk Adjusted Return 60.46% 75% C 69% C-
Market Capitalization 19.79B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 45.90 10% 7%
Price/Book Ratio 13.04 18% 7%
Price / Cash Flow Ratio 10.13 11% 7%
Price/Free Cash Flow Ratio 54.03 10% 8%
Management Effectiveness  
Return on Equity 24.43% 84% 87%
Return on Invested Capital 21.14% 87% 87%
Return on Assets 13.16% 90% 92%
Debt to Equity Ratio 48.50% 46% 48%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.